Homo and heterobimetallic palladium and platinum complexes bearing μ-diphosphane bridges involved in biological studies

Talita Kuijpers, B. Blom*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Citations (Web of Science)

Abstract

Given the increasing reports of well-defined bimetallic molecular complexes as potential anticancer agents in the last decades, along with the prevalence of platinum in anticancer therapy, we report here a detailed survey of bimetallic platinum and palladium complexes investigated as potential anticancer agents. Specifically, we will concentrate on the synthesis, characterisation and biological (anticancer) studies of a sub-class of these agents, namely homo and heterobimetallic complexes bearing a bridging phosphane ligand of the type: [LnM1(mu-R2P(CH2)(n)PR2)M2Lm] (where M-1 is platinum or palladium, M-2 is any other transition metal, R = alkyl or aryl substituents, L-n or L-m are co-ligands, n = 1-6). We will review the in vitro and in vivo activities and any mechanistic anticancer studies of these complexes with a view of trying to delineate patterns in biological activity and structure-activity relationships (SAR). We do not include the review of bimetallic complexes in this class that have not undergone any anticancer testing, nor those that have been involved in other biological investigations unrelated to cancer studies. (C) 2021 The Authors. Published by Elsevier Masson SAS.
Original languageEnglish
Article number113651
Number of pages24
JournalEuropean Journal of Medicinal Chemistry
Volume223
DOIs
Publication statusPublished - 5 Nov 2021

Keywords

  • Heterobimetallic complexes
  • Homobimetallic complexes
  • Palladium
  • Platinum
  • Anticancer activity
  • VERTICAL GROWTH-PHASE
  • ANTITUMOR-ACTIVITY
  • ANTICANCER ACTIVITY
  • BREAST-CANCER
  • IN-VITRO
  • SUBSTITUTION-REACTIONS
  • OXIDATIVE ADDITION
  • BBR 3464
  • CISPLATIN
  • DNA

Cite this